Related Experiment Videos

Pharmacotherapy of congestive heart failure in elderly patients

Peter C Burger1, Hanspeter Brunner-La Rocca

  • 1Clinic of Cardiology, University Hospital, Basel, Switzerland.

Journal of Cardiovascular Pharmacology and Therapeutics
|June 21, 2005
PubMed

Insights

Elderly patients with heart failure (HF) have limited data on treatment benefits. This review examines existing literature to better document outcomes for older adults with HF.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Increasing life expectancy and improved myocardial infarction survival lead to a growing elderly population with congestive heart failure (CHF).
  • Established drug classes like ACE inhibitors, ARBs, beta-blockers, and aldosterone antagonists show benefits in CHF patients.
  • Elderly individuals are often underrepresented in clinical trials for heart failure medications.

Purpose of the Study:

  • To critically review the current literature on the outcomes of heart failure therapy in elderly patients (aged 65 and older).
  • To address the documented gap in evidence regarding the efficacy of standard heart failure treatments in the geriatric population.

Main Methods:

  • Systematic literature review of randomized, placebo-controlled studies.
  • Analysis of studies focusing on heart failure treatment outcomes in patients aged 65 and older.
  • Critical appraisal of existing data concerning drug efficacy in elderly CHF subpopulations.

Main Results:

  • Evidence for the treatment benefit of standard heart failure medications in elderly patients is not well-documented.
  • Most large-scale studies excluded or had limited inclusion of elderly participants.
  • Further research is needed to establish definitive treatment guidelines for older adults with heart failure.

Conclusions:

  • The efficacy and safety of current heart failure therapies in the elderly require more robust investigation.
  • There is a need for dedicated clinical trials to include and evaluate older adults with heart failure.
  • Optimizing heart failure management in the growing geriatric population remains a critical clinical challenge.

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...